Description of theme 1
Description of theme 2
Description of theme 3
   
 

Hematology
P.O. Box 9101
6500 HB Nijmegen
The Netherlands
T: +31 24 366 8206
Fax +31 24 354 2080


T. de Witte is head of the department of Haematology, Radboud University Nijmegen Medical Centre since July 1990. He is professor in Haematology at the Radboud University Nijmegen from October 1990. T. de Witte has been active within several national and international scientific boards: chairman of the board of the Leukaemia Group of the EORTC  (2000-2003, and 2006-2009), treasurer and member board European Group for Blood and Marrow Transplantation (1996-2002), President of Dutch Society for Haematology (1994-2000), chairman of the board of  EuroCord Netherlands (2003-), chairman of the board of the Stem Cell Donor Bank Nijmegen (2003-), chairman of the EBMT Chronic Leukemia Working Party (2006-) and member of the board of the EBMT (2006-).
 
Prof. Dr. Theo M. de Witte

His research is focused around cellular immune responses involved in the graft-versus-tumor (GVT) reactivity after allogeneic Stem Cell Transplantation and Cellular Immunotherapy. Another priority within his research activities is the biology and treatment of the myelodysplastic syndromes (MDS) and poor-risk acute myeloid leukemia (AML). T. de Witte is study coordinator of  international studies in Myelodysplastic Syndromes(MDS) and acute myeloid leukaemia (AML) within EBMT and EORTC study groups. He coordinated a Biomed-2 project on molecular studies in MDS (Criant).  He is co-ordinator of the MDS Work Package of the European LeukemiaNET funded by the EU 6th Framework Programme (2003-). Radboud University Nijmegen Medical Centre has been recognised as a Centre of Excellence in the research, diagnosis, and treatment of MDS by The Myelodysplastic Syndromes Foundation in 1998. He has published more than 300 publications in international journals and 38 research fellows have successfully completed their PhD thesis with supervision of  T. de Witte.

 
 
Recent key publications

Ingrid M Overes, T Henriëtte Levenga, Johanna CM Vos, Agnes van Horssen-Zoetbrood, Robbert van der Voort, Pieter H de Mulder, Theo M de Witte, Harry Dolstra Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis.Cancer Immunol Immunother.2008 Aug 22

Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG, van der Voort R, Jedema I, Falkenburg JH, Schattenberg AV, de Witte TM, Dolstra H. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood. 2008 Dec 12.

van Wageningen S, Breems-de Ridder MC, Nigten J, Nikoloski G, Erpelinck-Verschueren CA, Löwenberg B, de Witte T, Tenen DG, van der Reijden BA, Jansen JH. Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha. Blood. 2008 Feb 1;111(3):1634-43.

Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol. 2008 Mar 1;26(7):1180; author reply 1181-2.

Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, García-Marco JA, Volin L, Schmitz N, Schwerdtfeger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European group for blood and marrow transplantation analysis. J Clin Oncol. 2008 Nov 1;26(31):5094-100.